Ibrance approval cemented as competition comes into viewIn February 2015, Pfizer’s Ibrance (palbociclib) was granted accelerated approval by the FDA for treatment of newly diagnosed Share XIbrance approval cemented as competition comes into viewhttps://pharmaphorum.com/partner-content-oncology/ibrance-approval-cemented-competition-comes-view/
